Literature DB >> 31134884

Yellow Fever: Factors Associated with Death in a Hospital of Reference in Infectious Diseases, São Paulo, Brazil, 2018.

Ana Freitas Ribeiro1,2, Roberta Figueiredo Cavalin1, Jamal Muhamad Abdul Hamid Suleiman1, Jessica Alves da Costa1, Marileide Januaria de Vasconcelos1, Ceila Maria Sant'Ana Málaque1, Jaques Sztajnbok1.   

Abstract

Faced with the reemergence of yellow fever (YF) in the metropolitan region of São Paulo, Brazil, we developed a retrospective study to describe the cases of YF attended at the Institute of Infectology Emilio Ribas from January to March 2018 and analyze the factors associated with death, from the information obtained in the hospital epidemiological investigation. A total of 72 cases of sylvatic YF were confirmed, with 21 deaths (29.2% lethality rate). Cases were concentrated in males (80.6%) and in the age group of 30 to 59 years (56.9%). Two logistic regression models were performed, with continuous variables adjusted for the time between onset of symptoms and hospitalization. The first model indicated age (odds ratiosadjusted [ORadj]: 1.038; CI 95%: 1.008-1.212), aspartate aminotransferase (AST) (ORadj: 1.038; CI 95%: 1.005-1.072), and creatinine (ORadj: 2.343; CI 95%: 1.205-4.553) were independent factors associated with mortality. The second model indicated age (ORadj: 1.136; CI 95%: 1.013-1.275), alanine aminotransferase (ALT) (ORadj: 1.118; CI 95%: 1.018-1.228), and creatinine (ORadj: 2.835; CI 95%: 1.352-5,941). The risk of death in the model with continuous variables was calculated from the increase of 1 year (age), 1 mg/dL (creatinine), and 100 U/L for AST and ALT. Another logistic regression analysis with dichotomous variables indicated AST > 1,841 IU/L (ORadj: 12.92; CI 95%: 1.50-111.37) and creatinine > 1.2 mg/dL (ORadj: 81.47; CI 95%: 11.33-585.71) as independent factors associated with death. These results may contribute to the appropriate clinical management of patients with YF in health-care services and improve the response to outbreaks and public health emergencies.

Entities:  

Mesh:

Year:  2019        PMID: 31134884      PMCID: PMC6609182          DOI: 10.4269/ajtmh.18-0882

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  19 in total

Review 1.  [Yellow Fever].

Authors:  Pedro Fernando da Costa Vasconcelos
Journal:  Rev Soc Bras Med Trop       Date:  2003-06-10       Impact factor: 1.581

2.  Hepatocyte lesions and cellular immune response in yellow fever infection.

Authors:  Juarez A S Quaresma; Vera L R S Barros; Carla Pagliari; Elaine R Fernandes; Heitor F Andrade; Pedro F C Vasconcelos; Maria I S Duarte
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-07-26       Impact factor: 2.184

3.  Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002.

Authors:  Suely Hiromi Tuboi; Zouraide Guerra Antunes Costa; Pedro Fernando da Costa Vasconcelos; Douglas Hatch
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-06-30       Impact factor: 2.184

4.  An epidemic of sylvatic yellow fever in the southeast region of Maranhao State, Brazil, 1993-1994: epidemiologic and entomologic findings.

Authors:  P F Vasconcelos; S G Rodrigues; N Degallier; M A Moraes; J F da Rosa; E S da Rosa; B Mondet; V L Barros; A P da Rosa
Journal:  Am J Trop Med Hyg       Date:  1997-08       Impact factor: 2.345

5.  The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases.

Authors:  Michael A Johansson; Pedro F C Vasconcelos; J Erin Staples
Journal:  Trans R Soc Trop Med Hyg       Date:  2014-06-30       Impact factor: 2.184

6.  Determinants of mortality from severe dengue in Brazil: a population-based case-control study.

Authors:  Giselle Hentzy Moraes; Eliane de Fátima Duarte; Elisabeth Carmen Duarte
Journal:  Am J Trop Med Hyg       Date:  2013-02-11       Impact factor: 2.345

7.  [Proteinuria, proteinaemia, and serum transaminase activity in 23 confirmed cases of yellow fever].

Authors:  J L Oudart; M Rey
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

8.  Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

Authors:  Thomas P Monath; Richard Nichols; W Tad Archambault; Linda Moore; Ron Marchesani; Jason Tian; Robert E Shope; Nicola Thomas; Robert Schrader; Dean Furby; Philip Bedford
Journal:  Am J Trop Med Hyg       Date:  2002-05       Impact factor: 2.345

9.  Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections.

Authors:  T P Monath; R B Craven; A Adjukiewicz; M Germain; D B Francy; L Ferrara; E M Samba; H N'Jie; K Cham; S A Fitzgerald; P H Crippen; D I Simpson; E T Bowen; A Fabiyi; J J Salaun
Journal:  Am J Trop Med Hyg       Date:  1980-09       Impact factor: 2.345

Review 10.  Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2016-06-20       Impact factor: 5.683

View more
  5 in total

1.  Yellow Fever Virus Reemergence and Spread in Southeast Brazil, 2016-2019.

Authors:  Marta Giovanetti; Marcos Cesar Lima de Mendonça; Vagner Fonseca; Maria Angélica Mares-Guia; Allison Fabri; Joilson Xavier; Jaqueline Goes de Jesus; Tiago Gräf; Cintia Damasceno Dos Santos Rodrigues; Carolina Cardoso Dos Santos; Simone Alves Sampaio; Flavia Lowen Levy Chalhoub; Fernanda de Bruycker Nogueira; Julien Theze; Alessandro Pecego Martins Romano; Daniel Garkauskas Ramos; Andre Luiz de Abreu; Wanderson Kleber Oliveira; Rodrigo Fabiano do Carmo Said; Carlos F Campelo de Alburque; Tulio de Oliveira; Carlos Augusto Fernandes; Shirlei Ferreira Aguiar; Alexandre Chieppe; Patrícia Carvalho Sequeira; Nuno Rodrigues Faria; Rivaldo Venâncio Cunha; Luiz Carlos Junior Alcantara; Ana Maria Bispo de Filippis
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

2.  Molecular Mechanism for Protection Against Liver Failure in Human Yellow Fever Infection.

Authors:  Fernanda de Oliveira Lemos; Andressa França; Antônio Carlos Melo Lima Filho; Rodrigo M Florentino; Marcone Loiola Santos; Dabny G Missiaggia; Gisele Olinto Libanio Rodrigues; Felipe Ferraz Dias; Ingredy Beatriz Souza Passos; Mauro M Teixeira; Antônio Márcio de Faria Andrade; Cristiano Xavier Lima; Paula Vieira Teixeira Vidigal; Vivian Vasconcelos Costa; Matheus Castro Fonseca; Michael H Nathanson; M Fatima Leite
Journal:  Hepatol Commun       Date:  2020-03-16

3.  Risk Factors for Acute Kidney Injury and Death in Patients Infected With the Yellow Fever Virus During the 2018 Outbreak in São Paulo, Brazil.

Authors:  Márcia Fernanda Arantes; Victor Faria Seabra; Paulo Ricardo Gessolo Lins; Camila Eleuterio Rodrigues; Bernardo Vergara Reichert; Marcelo Augusto Duarte Silveira; Ho Yeh Li; Luiz Marcelo Malbouisson; Lúcia Andrade
Journal:  Kidney Int Rep       Date:  2021-12-22

Review 4.  Recent sylvatic yellow fever virus transmission in Brazil: the news from an old disease.

Authors:  Natalia Ingrid Oliveira Silva; Lívia Sacchetto; Izabela Maurício de Rezende; Giliane de Souza Trindade; Angelle Desiree LaBeaud; Benoit de Thoisy; Betânia Paiva Drumond
Journal:  Virol J       Date:  2020-01-23       Impact factor: 4.099

5.  Staging liver fibrosis after severe yellow fever with ultrasound elastography in Brazil: A six-month follow-up study.

Authors:  Yuri Costa Sarno Neves; Victor Augusto Camarinha de Castro-Lima; Davi Jorge Fontoura Solla; Vivian Simone de Medeiros Ogata; Fernando Linhares Pereira; Jordana Machado Araujo; Ana Catharina Seixas Nastri; Yeh-Li Ho; Maria Cristina Chammas
Journal:  PLoS Negl Trop Dis       Date:  2021-07-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.